Pharmacogenomics in primary care: A crucial entry point for global personalized medicine?

Current Pharmacogenomics and Personalized Medicine

Volumn 10, Issue 2, 2012, Pages 101-105

  Bartlett, Gillian ^a   Zgheib, Nathalie ^b   Manamperi, Aresha ^c   Wang, Wei ^d,e,f   Hizel, Candan ^g,h   Kahveci, Rabia ^i,j   Yazan, Yasemin ^g  

^a MCGILL UNIVERSITY   (Canada)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c UNIVERSITY OF KELANIYA   (Sri Lanka)

^d EDITH COWAN UNIVERSITY   (Australia)

^e UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g ANADOLU UNIVERSITY   (Turkey)

^h C2H Vichy Genomics   (France)

ⁱ ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^j Turkish Evidence Based Medicine Association   (Turkey)

more..

Author keywords

Developing countries; Developing world genomics; Essential medicines; Genomics and international development; Global personalized medicine; Pharmacogenomics and primary care; Primary care genomics; Public health pharmacogenomics

Indexed keywords

AUSTRALIA; CHINA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG METABOLISM; EDITORIAL; GENETIC VARIABILITY; HEALTH INSURANCE; HUMAN; INDIAN OCEAN; LEBANON; MENTAL HEALTH; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIMARY HEALTH CARE; SRI LANKA; TERTIARY HEALTH CARE; TURKEY (REPUBLIC); WORLD HEALTH ORGANIZATION;

EID: 84861742673     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569212800626430     Document Type: Editorial

References (21)

1. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: Pharmacogenetics 2000; 320(7240): 987-90.
2. Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007; 4(8): e209.
3. Evans JP, Meslin EM, Marteau TM, et al. Deflating the genomic bubble. Science 2011; 331(6019): 861-2.
4. Grice GR, Seaton TL, Woodland AM, et al. Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics 2006; 7(1): 61-5.
5. van Weel C, Rosser WW. Improving health care globally: a critical review of the necessity of family medicine research and recommendations to build research capacity. Ann Fam Med 2004 May 1; 2(Suppl 2): S5-16.
6. Beasley JW, Starfield B, van Weel C, et al. Global health and primary care research. J Am Board Fam Med 2007; 20(6): 518-26.
7. Manamperi A. Current developments in genomics and personalized health care: Impact on public health. Asia Pac J Public Health 2008; 20(3): 242-50.
8. Aresha M, Sanath M, Deepika F, et al. Genotyping of Plasmodium vivax infections in Sri Lanka using Pvmsp-3alpha and Pvcs genes as markers: a preliminary report. Trop Biomed 2008; 25(2): 100-6.
9. Dias S, Somarathna M, Manamperi A, et al. Evaluation of the genetic diversity of domain II of Plasmodium vivax Apical Membrane Antigen 1 (PvAMA-1) and the ensuing strain-specific immune responses in patients from Sri Lanka. Vaccine 2011; 29(43): 7491-504.
10. Ozdemir V, Muljono DH, Pang T, et al. Asia-Pacific Health 2020 and Genomics without Borders: Co-Production of knowledge by science and society partnership for global personalized medicine. Curr Pharmacogenomics Person Med 2011; 9(1): 1-5.
11. Ling RE, Liu F, Lu XQ, et al. Emerging issues in public health: a perspective on China's healthcare system. Public Health 2011; 125(1): 9-14.
12. Zheng S, Song M, Wu L, et al. China: public health genomics. Public Health Genomics 2010; 13(5): 269-75.
13. Yun H, Hou L, Song M, et al. A New driver for novel moleculartargeted personalized medicine? Curr Pharmacogenomics Person Med 2012; 10(1): 16-21.
14. Hi{dotless}zel C, Gok S, Sardas S, et al. Personalized and predictive medicine in Turkey: A Symposium Report of the Istanbul Working Group on Personalized Medicine, Istanbul, Turkey, September 10-12, 2009. Curr Pharmacogenomics Person Med 2009; 7(4): 297-301.
15. Esmerian MO, Mitri Z, Habbal MZ, et al. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. J Clin Pharmacol 2011; 51(10): 1418-28.
16. Ghaddar F, Cascorbi I, Zgheib NK. Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. Pharmacogenomics 2011; 12(7): 1051-9.
17. Antoun J, Zgheib NK, Ashkar K. Education may improve the underutilization of genetic services by Middle Eastern primary care practitioners. Gent Test Mol Biomarkers 2010; 14(4): 447-54.
18. Zgheib N, Arawi T, Mahfouz R. Attitudes of health care professionals toward pharmacogenetic testing. Mol Diagnosis Therapy 2011; 15(2): 115-22.
19. Bajcar J, Wang L, Moineddin R, et al. From pharmaco-therapy to pharmaco-prevention: trends in prescribing to older adults in Ontario, Canada, 1997-2006. BMC Fam Pract 2010; 11(1): 75.
20. Schoen C, Osborn R, Huynh PT, et al. Primary care and health system performance: adults' experiences in five countries. Health Aff 2004; Suppl Web Exclusives: W4-487-503.
21. Corradetti C, Bartlett G. Democratizing Science. Public deliberation and the role of stakeholders as a new frontier in governance of science: comparing the BC Biobank deliberation and the DePGx project. Mascalzoni D, editor. Ethics, Law and Governance of Biobanking: National, European and International Profiles. Dordrecht: Springer; 2012.